Facilitating the Virtual Exercise Games for Youth with T1D (ExerT1D) Peer Intervention: Protocol Development and Feasibility

Author Affiliations: Garrett Ash, Ph.D.[1,2], Soohyun Nam, Ph.D., A.P.R.N., A.N.P.-B.C.[3], Matthew Stults-Kolehmainen, Ph.D., E.P.C.[4,5], Adrian D. Haughton, B.S.[1,6], Carolyn Turek, Ph.D.[7], Annette Chmielewski, M.S., R.D.[1], Michael Shelver, M.S., [1], Julien S. Baker, Ph.D.[8], Stuart A. Weinzimer, M.D.[3,9], Laura M. Nally, M.D.[9]

Garrett Ash
Department of Internal Medicine and Department of Biomedical Informatics and Data Science at Yale School of Medicine
Center for Pain, Research, Informatics, Medical Comorbidities and Education Center (PRIME) at VA Connecticut Healthcare System
Building 35A
950 Campbell Ave
West Haven, CT 06516
United States
Ph: 203-444-3079
Fax: 203-737-3550 (Attn: James Lukasik)
Garrett.ash@yale.edu

Soohyun Nam
Yale School of Nursing
P.O. Box 27399
West Haven, CT 06516-0972
United States
Ph: 203-737-2822
Fax: (203) 737-2414
Soohyun.Nam@yale.edu

Matthew Stults-Kolehmainen
Center for Weight Management
Yale New Haven Hospital
20 York St
New Haven, CT 06510
United States
Ph: 203-688-4242
Fax: 203-688-4645
Matthew.Stults@YNHH.ORG

Department of Biobehavioral Sciences
Teachers College – Columbia
525 W 120th St
New York, NY 10027
United States
Ph: (212) 678-3000
Fax: (212) 678-4048

Adrian Haughton
Department of Health and Movement Sciences Programs

Southern Connecticut State University
501 Crescent Street
New Haven, CT 06515
Ph: (203) 392-7278
Fax: (203) 392-6093
United States
Email: haughtonad@gmail.com

Carolyn Turek
Child Study Center
Yale School of Medicine
230 South Frontage Rd.
New Haven, CT 06520
United States
Ph: 1-844-362-9272
Fax: 203.737.5455
Email: carolyn.turek@yale.edu

Annette Chmielewski
Department of Internal Medicine
Yale School of Medicine
Building 35A
950 Campbell Ave
West Haven, CT 06516
United States
Ph: 203-444-3079
Fax: 203-737-3550 (Attn: James Lukasik)
Email: Annette.marie.c@gmail.com

Michael Shelver
Department of Internal Medicine
Yale School of Medicine
Building 35A
950 Campbell Ave
West Haven, CT 06516
United States
Ph: 203-444-3079
Fax: 203-737-3550 (Attn: James Lukasik)
Email: mike.shelver@gmail.com

Julien Baker
Centre for Health and Exercise Science Research
Population Health and Medical Informatics
Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR
China
Email: juliensbakerw@gmail.com

Stuart Weinzimer
Department of Pediatrics
Yale School of Medicine
333 Cedar Street

New Haven, CT 06520
United States
Ph: 203-785-5831
Fax: 203-764-6748 (Attn: James Lukasik)
Email: stuart.weinzimer@yale.edu

Yale School of Nursing
P.O. Box 27399
West Haven, CT 06516-0972
United States
Ph: 203-737-2822
Fax: (203) 737-2414

Laura Nally
Department of Pediatrics
Yale School of Medicine
333 Cedar Street
New Haven, CT 06520
United States
Ph: 203-785-5831
Fax: 203-764-6748 (Attn: James Lukasik)
United States
Laura.Nally@yale.edu

Abbreviations:
CGM, continuous glucose monitor
HbA1c, glycosylated hemoglobin
HIPAA, Health Insurance Portability and Accountability Act
IQR, interquartile range
MVPA, moderate-to-vigorous physical activity
T1D, type 1 diabetes

Keywords: Diabetes Mellitus, Type 1; Adolescent; Motivation; Exercise

Corresponding Author: Garrett Ash, Department of Internal Medicine, Department of Biomedical Informatics and Data Science, Yale School of Medicine, Building 35A, 950 Campbell Ave, West Haven, CT 06516; United States; email address Garrett.ash@yale.edu

Funding source: The study and G.I.A. were supported by American Heart Association Grant #852679 (G.I.A., 2021–2024) and a Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award, Bank of America, N.A., Trustee. G.I.A. and L.M.N. were supported by the National Institute of Diabetes, Digestive, and Kidney Diseases of the National Institutes of Health under mentored research scientist development awards (K01DK129441, K23DK128560). None of these entities were involved in the manuscript writing, editing, approval, or decision to publish.

Conflict-of-Interest Disclosure: S.A.W. receives grant support to his university from Abbott Laboratories. M.S. is employed as a product manager by Abbott

Laboratories and receives restricted stock units. L.M.N. receives funding for research from the National Institutes of Health and Medtronic Diabetes. She is also a consultant for Medtronic, WebMD and Calm. None of these entities supported the above study, and the authors conducted the research outside of their responsibilities and affiliations with these entities.

Acknowledgments: The authors thank the families and participants that help made this research possible. We also acknowledge Sa'Ra Skipper and Juanita Montoya for their assistance with conducting the study. Study data were collected and managed using REDCap electronic data capture tools hosted at Yale University.

Figure and table count: 2 figures, 3 tables

Word count: 3,000 / 3,000

ABSTRACT

Background: Barriers to moderate-to-vigorous physical activity (MVPA) for adolescents with type 1 diabetes (T1D) include physiology, transition to autonomy, and diabetes-specific stigma. Opportunities for T1D peer activities with T1D role model support are limited. To address this need, our single-arm pilot study tested Virtual Exercise Games for Youth with T1D (ExerT1D) for feasibility.

Method: The program included an MVPA videogame, physician-led education regarding managing T1D around MVPA, objective habitual MVPA goal-setting, and T1D management skills guided by young adult instructors living with T1D.

Results: Fifteen adolescents (median age 15.4 (IQR 14.5 - 16.4) years, 7 non-Hispanic white, 7 male, median HbA1c 7.8% (IQR 7.4%-11.2%) enrolled; 13 attended 83% of sessions. Participants rated the program, comfort, instructors, and group cohesion high/very high (4.2±0.5 to 4.8±0.3 out of 5). They also rated motivation for the videogame high (4.1±0.4 out of 5). Instructor-adolescent interactions related to building T1D management skills were rated as excellent for 78% of sessions by intervention evaluators. Similarly, sharing knowledge and experiences were rated as excellent for 68% of sessions. However, adolescent-adolescent interactions were rated poorly (communication 29% excellent, peer interactions 8% excellent). The most reported barriers to participation were negative mood and oversleeping. No participants experienced diabetic ketoacidosis, severe hypoglycemia, or injuries during the study period. Compared to baseline, glycemic metrics appeared to decrease over time (d= -1.12, 90% CI [-1.78, -0.48]).

Conclusions: Overall, ExerT1D facilitated excellent peer support by engaging diverse youth with T1D in an MVPA program led by role models living with T1D.

Abstract word count: 248 / 250

INTRODUCTION

The adolescent years present unique challenges for youth with type 1 diabetes (T1D). It is estimated that only 20% of youth meet the recommended A1c level below 7% shown to correlate with long-term health.[1,2] While physical activity can be leveraged to improve glycemia, weight, and cardiovascular risk factors, adolescents with T1D engage in less moderate-to-vigorous physical activity (MVPA) than the general adolescent population,[3] of which less than 10% meets the MVPA recommendations of the Centers for Disease Control and Prevention (60 minutes per day).[4] In youth with T1D, MVPA has been demonstrated to improve overall body composition, muscle strength, cardiopulmonary fitness, mental health), and diabetes-specific risks of glycemic outcomes, insulin resistance, and long-term cardiovascular complications.[5,6] Managing glycemia during MVPA requires more frequent glucose monitoring, adjustments to diet and insulin dosing, further in adolescence by puberty-specific hormones[5,7-9] which may impede adopting healthy, active behaviors. Barriers to physical activity reported by adolescents include the psychological fear of glycemic destabilization[10] and social stigma (i.e., “negative social judgments, stereotypes, prejudices”[11]) associated with disclosing an individual’s diagnosis when engaging in MVPA.[12] Thus, it is warranted to pursue multifaceted interventions targeted at addressing these barriers.

Current pediatric T1D MVPA guidelines are available but not actively understood or prescribed by most clinicians.[13] Additionally, there are limited data addressing feasibility, acceptability, safety, and efficacy of studies supporting physical activity for youth with low baseline MVPA.[5] Active videogames that incorporate physical activity into games using technology are a potential strategy to promote MVPA among youth.[14,15] Group activities incorporating active

videogame technology with T1D mentors provide an exciting new avenue to deliver all the components of a successful T1D self-management intervention:[16] 1) behavior modification (goal setting, self-monitoring); 2) psychosocial support (interactions with T1D peers and role models); and 3) medical guidance (MVPA safety monitoring and advice). Herein we present a single-arm prospective feasibility study evaluating the feasibility, acceptability, and safety of a virtual home intervention to promote MVPA among adolescents with T1D and estimate the probable effect on glycemic control to inform the design of an efficacy trial.

METHODS

Enrollment

Adolescents (14-19yr old, T1D ≥6mo) not achieving recommended MVPA targets (i.e., <4days/wk with 60+min self-reported[17]) were recruited from the Yale Children's Diabetes Center, clinicaltrials.gov (NCT05163912), and diabetes social media groups between December 23, 2021 and June 15, 2022. Screening was conducted by telephone using the Physical Activity Readiness Questionnaire verified against medical record.[18] For any health conditions presenting special considerations for MVPA, additional documentation was requested from the primary care physician or sub-specialist for MVPA clearance (n=1, arthritis). Informed consent or parental permission/assent (<18yr) was completed. The research team mailed supplies to the participant and held a HIPAA-compliant tele-video call (Zoom Video Communications, San Jose, CA) to confirm proper setup.

Participants fitted their home television monitor with a Nintendo Switch Entertainment System (Nintendo of America, Inc., Redmond, WA) including Ring Fit Adventure which alternates low- (stationary walking or jogging) with 60+ higher-intensity exercises that are dynamic (e.g., knee-lifts) or resistance-based

(e.g., abdominal press) tracked by a leg-strap accelerometer and handheld ring with gyroscopic/accelerometer sensors. Success with exercises unlocks more advanced adaptations (e.g., Russian twist). They were also provided a yoga mat, poster with Borg 6-20 rating of perceived exertion scale, Precision Xtra Blood Ketone meter and strips (Abbott Diabetes Care, Alameda, CA), and Fitbit Inspire 2 (Google, Menlo Park, CA). Sessions were livestreamed over Zoom (Figure 1).



Figure 1. Virtual exercise session livestreamed over Zoom.

<u>Intervention</u>

The intervention, based upon Social Cognitive Theory, integrated peer and role model interactions into home-based MVPA: livestreamed active videogame sessions and tele-video discussions about experiences self-monitoring MVPA and glucose.

Two role models living with T1D aged 20-26yr (non-Hispanic White male, non-Hispanic Black female) with physical activity experience facilitated the

sessions with a research assistant. Sessions were also monitored by clinicians (board-certified pediatric endocrinologist, certified diabetes care and education specialist) living with T1D and an exercise physiologist.

Participants were recruited in 4 sequential cohorts for a 6-week intervention with meetings twice weekly (Table S1) over Zoom. At the first session in each cohort, the pediatric endocrinologist (LN) gave an overview of safe exercise practices related to T1D management based on national and international guidelines.[7,8,19] Prior to activity, instructors confirmed that the participants had fast-acting carbohydrates accessible, proper exercise shoes and clothing, and a 2.4m-by-2.4m unobstructed space for exercise. At each session, before and after exercise, teens reported verbally or through the Zoom chat function their sensor glucose value and trend arrow, insulin dosing (last bolus and/or insulin-on-board), and ketone test results if the sensor glucose exceeded 250mg/dL or there were clinical concerns for elevated ketones. Clinical guidance was given by a clinician when ketones were elevated ≥0.6mmol/L. On a weekly basis, the pediatric endocrinologist reviewed continuous glucose monitor (CGM) and ketone data, identified any safety concerns, and communicated with participants and parents.

Participants communicated to the instructor if they needed to leave the session for any reason. For the purposes of coaching exercise, we tracked the proportion of each session spent in active movement, repetitions of each exercise, Borg 6-20 rating of perceived exertion of each exercise, and average Fitbit heart rate.

Following the 20-40min exercise activity, the last 20-30min of each session was spent on discussion over Zoom. Week 1 sessions were dedicated to creating individual fitness-related goals exercise goals, following the SMART principle (Specific, Measurable, Attainable, Relevant, Timely). In addition, participants in

each cohort formulated a group goal of cumulative achievements (e.g., group steps) to promote a cooperative rather than competitive approach.[20] Goal progress was checked and discussed each week, including the provision of MVPA and T1D management information that helped support the specific goals. During week 2-5 sessions, instructors engaged teens to create role-playing skits on Zoom that involved educational points related to T1D management. At the week 6 sessions, the instructors led a discussion about the relevance of the intervention's MVPA to building and sustaining an overall active lifestyle.

Assessments

Session recordings were double-coded by exercise physiologists to identify missed opportunities for practicing each core competency of a role model and peer intervention[21-25] which were then discussed with instructors weekly to iteratively improve the intervention. Participants also took a follow-up retrospective survey of acceptability including the motivation for exergame play inventory (α=0.79),[26] perceived cohesion scale (α=0.78-0.83),[27] and a satisfaction survey from our past work[22] to evaluate program components/strategies (5 items, α=0.72), personal comfort level (6 items, α=0.81), and interactions with instructors (12 items, α=0.95). Participants also rated their top-3 of these factors by importance.

Data Analysis

Study outcomes included recruitment uptake (≥35%),[28] attendance (≥75% attending ≥75% of sessions),[29] biosensor wear-time (≥70%),[30] survey completion (≥85%), fidelity ratings (≥70% excellent, ≥90% at least fair), and psychosocial perceptions of acceptability (≥3.0 out of 5). Variable distributions were described using visual inspection, Shapiro-Wilks test of normality, Levene's test of equal

variances, and appropriate effect size formulas where there appeared to be temporal trends (SPSSv28, Chicago, IL). We refined the curriculum based on data after each cohort, ending the trial when no further refinements were found. This sample size had 80% statistical power to detect any feasibility problems having ≥10% incidence.[31]

RESULTS

Participants

Fifteen participants referred by local providers, Facebook posts, and T1D community organizations were enrolled and completed follow-up (Figure S1), representing diverse geographic (8 states) and demographic characteristics: 8 people of color, 6 female, 2 non-binary, 4 public insurance, 2 household income below poverty line, and 7 household income <$60,000 (Table 1). Most participants had A1c levels above American Diabetes Association targets: 12 with A1c>7.0%, 5 with A1c>10.0%.

Table 1. Demographics. Mean±SD for normal distributed, median (interquartile range) otherwise).

	Recruited from Clinic	Recruited from Social Media	Total
N	7	8	15
Age (yr)[1]	15.6 (14.8, 17.0)	14.6 (14.4 – 16.2)	15.4 (14.5 - 16.4)
Gender	**3 female (43%)** **2 non-binary (29%)** 2 male (29%)	3 female (38%) 0 non-binary (0%) 5 male (62%)	6 female (40%) 2 non-binary (13%) 7 male (47%)
Pubertal Stage	0 Early (0%) 0 Mid (0%) 5 Late (71%) 2 Post (29%)	1 Early (13%) 3 Mid (38%) 3 Late (38%) 1 Post (13%)	1 Early (7%) 3 Mid (20%) 8 Late (53%) 3 Post (20%)
Race/Ethnicity	**1 non-Hispanic black (14%)** **4 Hispanic white or other (57%)** 0 more than one race 2 non-Hispanic white (29%)	2 non-Hispanic black (25%) 0 Hispanic white or other (0%) 1 more than one race (13%) 5 non-Hispanic white (63%)	3 non-Hispanic black (20%) 4 Hispanic white (27%) 1 more than one race (7%) 7 non-Hispanic white (47%)
A1c (%)[1]	**11.0 (7.4 – 12.0)** 7 over 7.0% (100%) **4 over 10.0% (57%)**	7.6 (6.7 – 8.0) 5 over 7.0% (63%) 1 over 10.0% (13%)	7.8 (7.4 – 11.2) 12 over 7.0% (67%) 5 over 10.0% (33%)
Duration of type 1 diabetes (yr)	8.0±4.1	8.4±3.8	8.2±3.8
Household income annual	**2 <$20,000 (29%)** **3 $40,00-$59,999 (43%)** 1 >$100,000 (14%) 1 declined to respond	0 <$20,000 (0%) 2 $40,000-$59,999 (25%) 3 $80,000-$99,999 (38%) 3 >$100,000 (38%) 0 declined to respond	2 <$20,000 (13%) 5 $40,000-$59,999 (33%) 3 $80,000-$99,999 (20%) 4 >$100,000 (27%) 1 declined to respond (7%)
Insurance (N public, %)	**3 (43%)**	1 (13%)	4 (27%)
Therapy	1 injections (14%) 4 sensor-augmented pump (57%) 2 automated insulin delivery (29%)	0 injections (0%) 7 sensor-augmented pump (88%) 1 automated insulin delivery (12%)	1 injections (7%) 11 sensor-augmented pump (73%) 3 automated insulin delivery (20%)
Prior CGM use (N, %)	7 (100%)	8 (100%)	15 (100%)
Total daily insulin dose (U/kg)	0.8±0.2	0.9±0.3	0.9±0.3
Body mass index (%'ile)[1]	76 (68 – 88)	70 (16 – 81)	67 (63 – 87)
Physical activity (days/wk with 60+ min MVPA)	**1.1±1.1**	1.8±1.0	1.5±1.1
Screen time (hours/day)	9.3±5.2	8.3±4.4	8.8±4.6

[1]Skewed distribution (age and HbA1c positive-skewed, body mass index negative-skewed).
Bolded figures indicate apparent difference from social media group.

Intervention Feasibility

Attendance

Thirteen participants attended ≥10/12 sessions, the other two attended 6. Absences were due to family activities (7), school activities (2), negative mood (6), oversleeping (6) or unexplained (2).

Technical Barriers

One participant missed most of one session due to “dead” controller, rated as moderate-high disruption, 2 days when they conversed by text chat due to phone audio interruption. Two other participants had Zoom connectivity interruptions on 1-2 occasions, which they reported caused mild disruption.

Fidelity

Instructor competencies were rated highest for building T1D and MVPA management skills followed by sharing T1D and MVPA knowledge and experiences, enriching communication at the group sessions, and facilitating peer interactions at the group sessions (Table 2). Most competencies trended upward for each successive cohort except for cohort #4. Cohort #3 was the largest size and most balanced with respect to race & ethnicity, income, HbA1c levels, and recruitment source (Table 3). Cohort #4 was tied for lowest size and had lowest attendance among those enrolled. One instructor covered the first two cohorts and the other the last two, both achieved similar average scores on most competencies.

Table 2. Fidelity, Satisfaction, Perceived Cohesion, and Exergaming Motivation Overall and by Cohort

	Instructor Competencies (% of sessions rated excellent)[1]				**Psychosocial Perceptions mean±SD (% rated ≥4 out of 5)**				**Exergaming Motivation mean±SD (% rated ≥4 out of 5)**
Cohort	**Building T1D and MVPA Management Skills**	**Sharing T1D and MVPA Knowledge and Experiences**	**Enriching Communication at the Group Sessions**	**Facilitating Peer Interactions at the Group Sessions**	**Interactions with Instructors**	**Group Cohesion (Perceived)**	**Program Components and Strategies**	**Comfort**	**Exergaming Motivation**
#1 (n=3)	75	58	25	0	4.6±0.7 (67%)	4.2±0.9 (67%)	4.1±0.2 (100%)	3.9±0.9 (67%)	3.8±0.4 (33%)
#2 (n=4)	100	90	46	27	4.9±0.0 (100%)	4.6±0.4 (100%)	4.5±0.3 (100%)	4.5±0.1 (100%)	4.1±0.2 (75%)
#3 (n=5)	100	100	50	0	4.9±0.2 (100%)	4.2±0.4 (80%)	4.3±0.6 (60%)	4.2±0.4 (80%)	3.9±0.2 (60%)
#4 (n=3)	38	25	0	0	4.8±0.3 (67%)	4.7±0.2 (100%)	4.3±0.7 (33%)	4.3±0.6 (33%)	4.6±0.2 (100%)
Total (n=15)	78	68	29	8	4.8±0.3 (93%)	4.4±0.5 (87%)	4.3±0.5 (73%)	4.2±0.5 (80%)	4.1±0.4 (60%)

[1]All other sessions were scored "fair" (i.e., none were scored "poor").
T1D, type 1 diabetes. MVPA, moderate-to-vigorous physical activity.
Cohort #4 took one week longer than expected to recruit the minimum 3 participants. In fairness to the 2 participants who signed up on the preset schedule, we offered them 2 sessions during the week of delay which were credited as extra sessions.

Table 3. Cohort Characteristics

Cohort	**Race/ Ethnicity**	**Gender**	**Age**	**Household Income (annual)**	**A1c**	**Recruitment**	**Attendance (Mean %)[1]**
#1 (n=3)	2 HispWhite 1 NHispWhite	1 NB 2 M	1, 14-15yr 2, 16-17yr	1 under $20k 2 under $60k	3 over 7.0% 1 over 10.0%	3 from clinic 0 from social media	75
#2 (n=4)	4 NHispWhite	4 M	3, 14-15yr 1, 16-17yr	0 under $20k 0 under $60k	2 over 7.0%	0 from clinic 4 from social media	92
#3 (n=5)	3 NHispBlack 1 More than 1 race 1 NHispWhite	1 NB 3 F 1 M	5, 14-15yr	0 under $20k 3 under $60k 1 not reported	5 over 7.0% 2 over 10.0%	2 from clinic 3 from social media	95
#4 (n=3)	2 HispWhite 1 NHispWhite	3 F	1 14-15yr 1, 16-17yr 1, 18-19yr	1 under $20k 2 under $60k	2 over 10.0%	2 from clinic 1 from social media	72

HispWhite, Hispanic White. NHispWhite, Non-Hispanic White. NHispBlack, Non-Hispanic Black. NB, non-binary. M, male. F, Female.
[1]Cohort #4 took one week longer than expected to recruit the minimum 3 participants. In fairness to the 2 participants who signed up on the preset schedule, we offered them 2 sessions during the week of delay which were credited as extra sessions.

Intervention Acceptability

Participant satisfaction ratings were highest for interactions with instructors, followed by perceived group cohesion, program components and strategies, comfort, and lastly, Ring Fit game motivation (Table 3). The instructor component was also most frequently selected as a top-1 or top-3 (80%, 60%).

Intervention Safety and Monitoring

No participants experienced diabetic ketoacidosis, severe hypoglycemia, or other study-related adverse events during the study period. One participant developed elevated ketone levels prior to exercise (1.1 mmol/L), that resolved after insulin administration prior to exercise. One participant deferred exercise due to feeling unwell as a result of having a high sensor glucose level (400mg/dL) without elevated ketones. Three participants reported hypoglycemia symptoms during 1 session (resolved by carbohydrates) and three had sensor glucose levels <70mg/dL less than 1 hour after 1 of the sessions (resolved without staff guidance).

All participants were using a CGM in their clinical care before the study (12 Dexcom G6, 3 Abbott Libre 2). Weekly CGM audits found 73.6% of the possible readings were captured across all study participants. Ten participants met the recommended ≥70% completeness. Weekly CGM physician reviews resulted in 4 participants being referred to their providers for insulin dose adjustments to address elevated percentages of low sensor glucose values. Topics related to avoiding hypoglycemia after exercise were also discussed in the group lesson, and trends were also addressed with participants directly.

Fitbit heart rates were captured for 96/117 person-sessions (82%), with 14 having at least one session. Among them, 1 averaged in the vigorous range of 70%-90% age-predicted maximum, 12 averaged in the moderate range of 55%-

70%, and 1 averaged below the moderate range. The average participant heart rate across sessions was 61.4±5.2% of maximum.

Intervention Activities

Participants set individual and group goals related to achieving Fitbit step counts, playing a sport, playing Ring Fit outside of group sessions, or managing diabetes (Table S2) with ~40% success.

Fitbit wear time on average met literature standards (70.5%, or 16.9 hours per day suggesting an average of 10-15 hours during waketime).[30] Cohort 1 participants stopped wearing the Fitbit 2-4 weeks into the program, so we inserted a biweekly check of wear-time and troubleshooting after which this pattern did not repeat. Average steps for those with Fitbit step goals were 8274±3734 per day and for the total sample were 7178±4013 per day.

Each skit successfully integrated 3-5 educational points (Table S3).

Ancillary Analysis of Glycemic Outcomes

Metrics of average glucose visually trended downward over time (Figure 2). HbA1c at follow-up was on average lower than baseline (8.9% vs 8.3%) but equally positive-skewed (Levene's $F_{1,2}$=0.458, P=.50). Such effect is best standardized as the Wilcoxon Signed Rank test statistic W= -1.905, equal to biserial r= -0.49 or Cohen's d= -1.12 (90% CI [-1.78, -0.48]) (i.e., probably a medium or large effect).[32] Insulin delivery did not appear responsible for changes since total daily dose decreased (0.88±0.27 to 0.83±0.24 U/kg) and participants upgrading to a closed-loop system during follow-up (n=7) had the same average HbA1c change as the full cohort. Body mass index percentile remained negative-skewed and unchanged (median 67 vs 66, mean 75 vs 75, IQR 63-87 vs 53-86).



Figure 2. Glycemic metrics over time. **Top.** Metrics indicating average glucose (n=15). Baseline is laboratory HbA1c taken an average of 7 weeks (range 1-14) before intervention start, extracted from medical record. Weeks 1-6 are glucose management indicator (GMI) over the course of the intervention, which project HbA1c based on continuous glucose monitor (CGM) data. Follow-up is laboratory HbA1c taken an average of 45 weeks (range 19-77) after intervention start, extracted from medical record. Missing values (1 participant at weeks 1-6 due to not sharing downloadable CGM data, 2 participants at follow-up due to not sharing long-term access to medical record) were imputed by intention-to-treat, last observation carried forward. Dash through box indicates median, plus sign indicates mean, box indicates interquartile range, whiskers indicate minimum and maximum. **Bottom.** Metrics indicating time in glucose ranges (n=14). Clinical targets were met for time in hypoglycemia level 1 (1.8%-2.2% vs target ≤4%) and level 2 (0.5%-0.7% vs target ≤1%), but not hyperglycemia (42%-51% vs target ≤25%) or in target range (46%-55% vs target ≥70%). Data completeness at the participant level was 79% (SD 25%) with 10 participants at ≥70% and 4 participants at 24%-54%. The 1 participant who did not share downloadable CGM data was excluded. CGM data were not processed outside of the intervention window since 5 participants had not worn it at all for the two weeks before enrollment.

DISCUSSION

The primary finding of the study was that the virtual, compared to in-person protocol,[21] greatly increased feasibility while maintaining excellent safety standards. Compared to our in-person group, we doubled recruitment uptake proportion from 16% to 35%, which is comparable to 37% seen in personalized MVPA prescription for T1D that did not require fitting a group schedule.[28] We also expanded from clinic to social media venues. In addition, we improved the attendance from 56% to 85%-90%, while also doubling the frequency of sessions from once to twice per week. A glucose monitoring protocol was followed with no adverse events and occurrence of MVPA-induced hypoglycemia no more frequently than typical daily living. The program was also highly cost-efficient. Social media advertisements utilized community postings rather than paid advertisements, and virtual technology was all within the scope of devices normally owned by diverse families of teens with T1D. Videogame technology is popular among teens and substantially more so among those from lower-income families.[33]

The high acceptability of the in-person protocol[22] was also maintained based on mean evaluation scores, though unbalanced across subscales. Intervention delivery competencies that could be directly delivered from young adult role model instructors – sharing T1D and MVPA knowledge and experiences and building T1D and MVPA self-management skills – achieved an excellent rating at 68%-78% of sessions. By contrast, those that depended upon teen-to-teen interactions were achieved excellently much less often. Similarly, instructor interactions were the most highly rated and most important component of the program to teens. Perceived group cohesion was also rated highly by the teens, reflecting some combination of perceived cohesion to the instructors and other teens. Program structure and comfort were rated less highly than instructor

interactions and perceived group cohesion, though nonetheless received ratings of 4+ out of 5 and were likely essential to the program's feasibility.

Prior studies supporting MVPA for adolescents with T1D provided self-management education and decision guidance[28,34-36] and only one included personal support, which came from key family members such as a parent.[28] In real-world contexts, 91% of adolescents with T1D report that their parents discourage MVPA[10] and that teachers and coaches have limited T1D knowledge.[37] Therefore, interventions aimed at improving health outcomes need to be introduced during the transition period of adolescence when youth are developing the skills they will need as adults to manage T1D.[21,22]

Support from peers and peer mentors is rated as important by adolescents with T1D[38,39] and associated with increased diabetes self-care.[40] However, the incorporation of peers and role models is in nascent stages[23,41] and mostly focused on T1D-specific behaviors rather than those important for general health such as MVPA. Such restriction of peer support to T1D-specific behaviors has been negatively associated with diabetes self-care,[40] similar to the "nagging" perceived from parents.[42] It may also be less engaging, as these prior peer interventions have been almost entirely restricted to asynchronous communications without physical activities.[24,25] When synchronous chats have been added, just 39%-48% of participants attended one or more sessions.[25,41] Overall, the present study shows the promise of peer group MVPA as a novel strategy both for supporting MVPA and generally engaging adolescents with T1D.

A major strength of the study was the enrollment of a diverse sample of adolescents in greatest need of support for MVPA and T1D self-management (lower income, people of color, elevated HbA1c).[43] This study had no A1c upper

limit, thus incorporating a group of youth with T1D at high risk of dysglycemia that has been largely excluded from research studies. Intervention attendance was excellent and overcame logistical barriers related to alignment of group schedules, availability of MVPA supplies, timing MVPA with insulin and diet, and provision of real-time guidance. Given the focus on feasible uptake of technology and inclusion of youth with all HbA1c levels, we enrolled participants even if they were wearing their CGM inconsistently at enrollment, which meant glycemic outcomes could only be assessed by combining HbA1c and GMI values in an ancillary analysis. HbA1c and GMI can be discordant due to the timeframe they reflect and non-glycemic factors that can impact HbA1c.[44] Nonetheless, glycemic reductions were seen during and after the intervention. These findings were encouraging, especially in light of the elevated HbA1c levels in the cohort at baseline, as these youth are largely excluded from research.

We acknowledge some limitations of the intervention. While participants perceived high group cohesion, they had minimal verbal interactions with each other. Instructors were trained in group facilitation strategies derived from our expert planning group discussions and two pilot sessions, but for future studies we will utilize an accredited group facilitation course. Peer interactions might also be enhanced by interoperable virtual reality technology that creates a more immersive experience. Second, Fitbit measurements of heart rate may be less accurate for those with darker skin tone.[45] However, Fitbit was mainly used for step-counting which does not have this limitation, and heart rate was only used for an assessment of convergent validity with the validated videogame.[46] That the study was limited to those who were able to afford Internet access at home, had television/computer screens, and time to attend the sessions does limit some generalizability and implementation. Finally, as a small single-group study design,

we had limited ability to robustly determine efficacy outcomes.

CONCLUSIONS

In summary, we report protocol development and feasibility of a virtual home intervention to promote MVPA among peer groups of adolescents with T1D. Successes included attraction of a diverse group, high attendance at the sessions, T1D self-management guidance that promoted safe MVPA, and meaningful connections to role-model instructors including shared experiences and skills in T1D self-management and coping. The challenge was promoting immersive interaction among the adolescents. Therefore, future trials testing efficacy and moderators warrant upgrades of delivery to include more immersive virtual reality technologies and financial investment to integrate and interoperate the components of our curriculum: MVPA, discussion, skits, viewership of glucose, and insulin dosing. The advantages of our program were effectiveness at connecting teens to young adult role models in a way that was logistically feasible, time efficiency for the role models since they could interact with a group all at once, and sustainment of favorable MVPA and clinical metrics. The relative limitations were the capability to facilitate peer interactions and have an enjoyable MVPA experience. It may therefore be beneficial to integrate our curriculum into more immersive technology such as virtual reality headsets allowing interactions through avatars.

DATA AVAILABILITY

Individual de-identified participant data (including data dictionaries) were shared. This includes individual participant data that underlies the results reported in any aspect of a published article (text, tables, figures, and appendices). Other documents that will be available include the study protocol, statistical analysis plan, informed consent form, and analysis code. The data will be available immediately

following publication, with no end dates. The data will be shared with researchers who provide a methodologically sound proposal to achieve the aims of the approved proposal. The proposals should be directed to Dr. Garrett Ash at Yale University (garrett.ash@yale.edu). To gain access, data requesters must sign a data access agreement.

AUTHORSHIP CONFIRMATION/CONTRIBUTION STATEMENT

GIA: Conceptualization (lead), data curation (lead), formal analysis (lead), funding acquisition (lead), investigation (equal), methodology (equal), project administration (lead), resources (lead), software (support), supervision (lead), validation (equal), visualization (lead), writing – original draft (lead). **SN:** Conceptualization (equal); investigation (equal); methodology (equal); writing – review and editing (equal). **MSK:** Methodology (supporting); Writing – review and editing (equal). **ADH:** Investigation (equal); methodology (equal); project administration (equal); software (equal); writing, review, and editing (supporting). **CT:** Investigation (equal); methodology (equal); writing, review, and editing (equal). **AC:** Investigation (equal); methodology (equal); writing – review and editing (equal). **MS:** Investigation (equal); methodology (equal); writing, review, and editing (equal). **JSB:** Methodology (supporting); Writing – review and editing (equal). **SAW:** Conceptualization (equal); investigation (equal); methodology (equal); writing – review and editing (equal); writing – review and editing (equal). **LMN:** Conceptualization (equal), formal analysis (equal), investigation (equal), methodology (lead), software (lead), visualization (equal), writing – review and editing (lead).

REFERENCES

1. Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes

technology & therapeutics 2019;21(2):66-72, doi:10.1089/dia.2018.0384 [doi]
2. Nathan DM, Group DER. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes care 2014;37(1):9-16, doi:10.2337/dc13-2112 [doi]
3. Elmesmari R, Reilly JJ, Martin A, et al. Accelerometer measured levels of moderate-to-vigorous intensity physical activity and sedentary time in children and adolescents with chronic disease: A systematic review and meta-analysis. PloS one 2017;12(6):e0179429, doi:10.1371/journal.pone.0179429 [doi]
4. Tapia-Serrano MA, Sevil-Serrano J, Sanchez-Miguel PA, et al. Prevalence of meeting 24-Hour Movement Guidelines from pre-school to adolescence: A systematic review and meta-analysis including 387,437 participants and 23 countries. J Sport Health Sci 2022;11(4):427-437, doi:10.1016/j.jshs.2022.01.005
5. Adolfsson P, Taplin CE, Zaharieva DP, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in children and adolescents with diabetes. Pediatr Diabetes 2022;23(8):1341-1372, doi:10.1111/pedi.13452
6. Pongrac Barlovic D, Harjutsalo V, Groop PH. Exercise and nutrition in type 1 diabetes: Insights from the FinnDiane cohort. Front Endocrinol (Lausanne) 2022;13(1064185, doi:10.3389/fendo.2022.1064185
7. Moser O, Riddell MC, Eckstein ML, et al. Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Pediatric diabetes 2020;21(8):1375-1393, doi:10.1111/pedi.13105 [doi]
8. Riddell MC, Gallen IW, Smart CE, et al. Exercise management in type 1 diabetes: a consensus statement. The lancetDiabetes & endocrinology 2017;5(5):377-390, doi:S2213-8587(17)30014-1 [pii]
9. Amiel SA, Sherwin RS, Simonson DC, et al. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. The New England journal of medicine 1986;315(4):215-219, doi:10.1056/NEJM198607243150402 [doi]
10. Jabbour G, Henderson M, Mathieu ME. Barriers to Active Lifestyles in Children with Type 1 Diabetes. Canadian journal of diabetes 2016;40(2):170-172, doi:10.1016/j.jcjd.2015.12.001 [doi]
11. Speight J, Holmes-Truscott E, Garza M, et al. Bringing an end to diabetes stigma and discrimination: an international consensus statement on evidence and recommendations. Lancet Diabetes Endocrinol 2024;12(1):61-82, doi:10.1016/S2213-8587(23)00347-9
12. Lawton K. People with type 1 diabetes held back from sport due to stigma and fear of hypos. Juvenile Diabetes Research Foundation: 2023.
13. Chinchilla P, Dovc K, Braune K, et al. Perceived Knowledge and Confidence for Providing Youth-Specific Type 1 Diabetes Exercise Recommendations amongst Pediatric Diabetes Healthcare Professionals: An International, Cross-Sectional, Online Survey. Pediatric Diabetes 2023;2023(8462291, doi:10.1155/2023/8462291
14. Benzing V, Schmidt M. Exergaming for Children and Adolescents: Strengths, Weaknesses, Opportunities and Threats. Journal of clinical medicine 2018;7(11):422. doi: 10.3390/jcm7110422, doi:10.3390/jcm7110422 [doi]
15. Council On C, Media. Media Use in School-Aged Children and Adolescents. Pediatrics 2016;138(5), doi:10.1542/peds.2016-2592

16. Akhter K, Turnbull T, Simmons D. A systematic review of parent/peer-based group interventions for adolescents with type 1 diabetes: interventions based on theoretical/therapeutic frameworks. Br J Diabetes 2018;18(51-65

17. Prochaska JJ, Sallis JF, Long B. A physical activity screening measure for use with adolescents in primary care. Archives of Pediatrics & Adolescent Medicine 2001;155(5):554-559

18. Warburton DE, Gledhill N, Jamnik VK, et al. Evidence-based risk assessment and recommendations for physical activity clearance: Consensus Document 2011. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2011;36 Suppl 1(S266-98, doi:10.1139/h11-062 [doi]

19. Adolfsson P, Riddell MC, Taplin CE, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Exercise in children and adolescents with diabetes. Pediatric diabetes 2018;19 Suppl 27(205-226, doi:10.1111/pedi.12755 [doi]

20. Staiano AE, Abraham AA, Calvert SL. Motivating effects of cooperative exergame play for overweight and obese adolescents. Journal of diabetes science and technology 2012;6(4):812-819, doi:dst.6.4.0812 [pii]

21. Ash GI, Joiner KL, Savoye M, et al. Feasibility and safety of a group physical activity program for youth with type 1 diabetes. Pediatric diabetes 2019, doi:10.1111/pedi.12841 [doi]

22. DeJonckheere M, Joiner KL, Ash GI, et al. Youth and Parent Perspectives on the Acceptability of a Group Physical Activity and Coping Intervention for Adolescents With Type 1 Diabetes. Sci Diabetes Self Manag Care 2021;47(5):367-381, doi:10.1177/26350106211040429

23. Titoria R, Amed S, Tang TS. Peer Support Interventions on Digital Platforms for Children With Type 1 Diabetes and Their Caregivers. Diabetes Spectr 2022;35(1):26-32, doi:10.2337/ds21-0081

24. Walker AF, Haller MJ, Gurka MJ, et al. Addressing health disparities in type 1 diabetes through peer mentorship. Pediatr Diabetes 2020;21(1):120-127, doi:10.1111/pedi.12935

25. Troncone A, Cascella C, Chianese A, et al. Psychological support for adolescents with type 1 diabetes provided by adolescents with type 1 diabetes: The chat line experience. Pediatric diabetes 2019;20(6):800-810, doi:10.1111/pedi.12873 [doi]

26. Staiano AE, Adams MA, Norman GJ. Motivation for Exergame Play Inventory: Construct validity and relationship to game play. Cyberpsychology: Journal of Psychosocial Research on Cyberspace 2019;13(3):Article 7, doi:10.5817/CP2019-3-7

27. Chin WW, Salisbury WD, Pearson AW, et al. Perceived Cohesion in Small Groups: Adapting and Testing the Perceived Cohesion Scale in a Small-Group Setting. Small Group Research 1999;30(6):751-766, doi:10.1177/104649649903000605

28. Faulkner MS, Michaliszyn SF, Hepworth JT, et al. Personalized exercise for adolescents with diabetes or obesity. Biological research for nursing 2014;16(1):46-54, doi:10.1177/1099800413500064 [doi]

29. Quirk H, Blake H, Tennyson R, et al. Physical activity interventions in children and young people with Type 1 diabetes mellitus: a systematic review with meta-analysis. Diabetic medicine : a journal of the British Diabetic Association 2014;31(10):1163-1173, doi:10.1111/dme.12531 [doi]

30. Troiano RP, Berrigan D, Dodd KW, et al. Physical activity in the United States measured by accelerometer. Medicine and science in sports and exercise

2008;40(1):181-188, doi:10.1249/mss.0b013e31815a51b3
31. Viechtbauer W, Smits L, Kotz D, et al. A simple formula for the calculation of sample size in pilot studies. Journal of clinical epidemiology 2015;68(11):1375-1379, doi:10.1016/j.jclinepi.2015.04.014 [doi]
32. Fritz CO, Morris PE, Richler JJ. Effect size estimates: current use, calculations, and interpretation. J Exp Psychol Gen 2012;141(1):2-18, doi:10.1037/a0024338
33. Gottfried JS, O. Teens and Video Games Today. 2024. Available from: https://www.pewresearch.org/internet/2024/05/09/teens-and-video-games-today/.
34. Wong CH, Chiang YC, Wai JP, et al. Effects of a home-based aerobic exercise programme in children with type 1 diabetes mellitus. Journal of Clinical Nursing 2011;20(5-6):681-691, doi:10.1111/j.1365-2702.2010.03533.x [doi]
35. Marrero DG, Fremion AS, Golden MP. Improving compliance with exercise in adolescents with insulin-dependent diabetes mellitus: results of a self-motivated home exercise program. Pediatrics 1988;81(4):519-525
36. Shetty VB, Soon WHK, Roberts AG, et al. A Novel Mobile Health App to Educate and Empower Young People With Type 1 Diabetes to Exercise Safely: Prospective Single-Arm Mixed Methods Pilot Study. JMIR Diabetes 2021;6(4):e29739, doi:10.2196/29739
37. Ryninks K, Sutton E, Thomas E, et al. Attitudes to Exercise and Diabetes in Young People with Type 1 Diabetes Mellitus: A Qualitative Analysis. PloS one 2015;10(10):e0137562, doi:10.1371/journal.pone.0137562 [doi]
38. Ye CY, Jeppson TC, Kleinmaus EM, et al. Outcomes That Matter to Teens With Type 1 Diabetes. The Diabetes educator 2017;43(3):251-259, doi:10.1177/0145721717699891 [doi]
39. Xie LF, Housni A, Nakhla M, et al. Adaptation of an Adult Web Application for Type 1 Diabetes Self-management to Youth Using the Behavior Change Wheel to Tailor the Needs of Health Care Transition: Qualitative Interview Study. JMIR Diabetes 2023;8(e42564, doi:10.2196/42564
40. Doe E. An analysis of the relationships between peer support and diabetes outcomes in adolescents with type 1 diabetes. J Health Psychol 2018;23(10):1356-1366, doi:10.1177/1359105316656228
41. Bisno DI, Reid MW, Pyatak EA, et al. Virtual Peer Groups Reduce HbA1c and Increase Continuous Glucose Monitor Use in Adolescents and Young Adults with Type 1 Diabetes. Diabetes Technol Ther 2023;25(9):589-601, doi:10.1089/dia.2023.0199
42. Luyckx K, Seiffge-Krenke I, Missotten L, et al. Parent-adolescent conflict, treatment adherence and glycemic control in Type 1 diabetes: the importance of adolescent externalising symptoms. Psychol Health 2013;28(9):1082-97, doi:10.1080/08870446.2013.782405
43. Armstrong S, Wong CA, Perrin E, et al. Association of Physical Activity With Income, Race/Ethnicity, and Sex Among Adolescents and Young Adults in the United States: Findings From the National Health and Nutrition Examination Survey, 2007-2016. JAMA pediatrics 2018, doi:10.1001/jamapediatrics.2018.1273 [doi]
44. Piona C, Marigliano M, Mozzillo E, et al. Evaluation of HbA1c and glucose management indicator discordance in a population of children and adolescents with type 1 diabetes. Pediatr Diabetes 2022;23(1):84-89, doi:10.1111/pedi.13299
45. Koerber D, Khan S, Shamsheri T, et al. Accuracy of Heart Rate Measurement with Wrist-Worn Wearable Devices in Various Skin Tones: a Systematic Review. J Racial Ethn Health Disparities 2022;1-9,

doi:10.1007/s40615-022-01446-9
46. Comeras-Chueca C, Villalba-Heredia L, Pérez-Llera M, et al. Assessment of Active Video Games' Energy Expenditure in Children with Overweight and Obesity and Differences by Gender. International journal of environmental research and public health 2020;17(18):6714. doi: 10.3390/ijerph17186714, doi:10.3390/ijerph17186714 [doi]

Supplemental Material
Ash et al.
Facilitating the Virtual Exercise Games for Youth with T1D (ExerT1D) Peer Intervention: Protocol Development and Feasibility



Figure S1. Enrollment flow-chart. *Online advertising consisted of Children with Diabetes posting the advertisement in three issues of their weekly newsletter (February 9th–February 23rd, 2022) as well as their Facebook page on February 15th. The Facebook post received 12 likes, 10 shares, and 23 email inquiries as listed. †One participant required clearance for a medical condition from a specialist (arthritis) prior to enrollment.

Table S1. Structure of intervention sessions.

Component	Saturdays Time of Day[1]	Wednesdays Time of Day
Icebreaker question	10:00-10:05	19:00-19:05
Sensor glucose check and guidance[2]	10:05-10:20	19:05-19:20[3]
Exercise	10:20-11:00	19:20-19:40[3]
Sensor glucose check and guidance	11:00-11:05	19:40-19:45[3]
Discussion Activities • MVPA goals (**week 1**: set goals; **weeks 2-5:** check progress and provide MVPA and T1D management information supporting goals; **week 6:** reflection on relationship to overall active lifestyle) • Role-playing skits (**weeks 2-5:** planning and acting)	11:05-11:30	19:45-20:00

[1]USA eastern time zone, which was the local time of all participants except 1 who was USA mountain time zone (2 hours earlier)

[2]Extended to 30 minutes at first session to give general overview of guidelines. This session had reduced exercise by 8 minutes and discussion activities by 5-10 minutes.

[3]Cohort #1 only had these components on Saturdays (i.e., Wednesday session only met 19:00-19:20). Added these components to Wednesdays per expressed interest of cohort #2.

Table S2. Individual Goals (n=15)

Goal Category	Number of participants	Specific Value	Achieved Goal
Steps	6	School to home, 3d/week 4000 per day 7000 per day 8500 per day 10000 per day 12500 per day	2 / 6 (33%)
Sport	5	Find a soccer group Bike 26.2 miles Run 8:00 mile Run 6:35 mile Run 7:30 pace for 5 miles	2 / 5 (40%)
Ring Fit	3	20 minutes per day 500 reps of 1 specific movement Reach world 9	1 / 3 (33%)
Diabetes management	1	7.0% estimated A1c from CGM	0 / 1 (0%)
Total	15		5 / 15 (33%)

Table S3. Structure of topics, roles, and competencies taught during skits for each cohort.

Cohort	Topic	Roles[1]	Educational Points and How Integrated
1	Team sports and type 1 diabetes (T1D)	-Athlete with newly diagnosed with T1D -Teammate living with T1D for several years -Continuous glucose monitor with alerts -Coach	-Speaking to coaches who are not familiar with T1D management around MVPA -Peer mentoring -Competitive sports and glycemic management
2 & 3	Zombie Apocalypse	-Zombie -Zombie-killing engineer -Teen newly diagnosed with T1D and knows nothing about what they need for T1D management during an apocalypse -Teen with longer duration of T1D -Dr. Rescue -News host -Continuous glucose monitor with alerts	-Essential supplies for T1D -Prioritizing aspects of T1D management -Operating continuous glucose monitors -Impact of MVPA on glycemic management -Impact of stress on glycemic management
4	Wilderness Excursion	-Lilo (Hawaiian girl) -Stitch (helpful alien) -Evil singing crab -Battler of evil singing crab -Diabuddy (diabetes buddy) -Angel -Narrator	-Same as Zombie Apocalypse

[1]Self-chosen by interested participants, remaining ones assigned.
MVPA, moderate-to-vigorous physical activity

Table S4. CONSORT 2010 checklist of information to include when reporting a pilot or feasibility trial*

Section/Topic	Item No	Checklist item	Reported on line No
Title and abstract			
	1a	Identification as a pilot or feasibility randomised trial in the title	Title (page 1)
	1b	Structured summary of pilot trial design, methods, results, and conclusions (for specific guidance see CONSORT abstract extension for pilot trials)	2-25 of abstract (page 5)
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale for future definitive trial, and reasons for randomised pilot trial	28-57
	2b	Specific objectives or research questions for pilot trial	58-60
Methods			
Trial design	3a	Description of pilot trial design (such as parallel, factorial) including allocation ratio	57-58
	3b	Important changes to methods after pilot trial commencement (such as eligibility criteria), with reasons	None
Participants	4a	Eligibility criteria for participants	63-64
	4b	Settings and locations where the data were collected	75-84
	4c	How participants were identified and consented	63-72
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	89-129
Outcomes	6a	Completely defined prespecified assessments or measurements to address each pilot trial objective specified in 2b, including how and when they were assessed	131-140
	6b	Any changes to pilot trial assessments or measurements after the pilot trial commenced, with reasons	None
	6c	If applicable, prespecified criteria used to judge whether, or how, to proceed with future definitive trial	143-146
Sample size	7a	Rationale for numbers in the pilot trial	149-152
	7b	When applicable, explanation of any interim analyses and stopping guidelines	None
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	N/A
	8b	Type of randomisation(s); details of any restriction (such as blocking and block size)	N/A
Allocation concealment	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	N/A

mechanism			
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	N/A
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	N/A
	11b	If relevant, description of the similarity of interventions	N/A
Statistical methods	12	Methods used to address each pilot trial objective whether qualitative or quantitative	143-149
Results			
Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were approached and/or assessed for eligibility, randomly assigned, received intended treatment, and were assessed for each objective	Supplement Figure S1
	13b	For each group, losses and exclusions after randomisation, together with reasons	Supplmeent Figure S1
Recruitment	14a	Dates defining the periods of recruitment and follow-up	66
	14b	Why the pilot trial ended or was stopped	149-152
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1
Numbers analysed	16	For each objective, number of participants (denominator) included in each analysis. If relevant, these numbers should be by randomised group	Tables 2 & 3, Figure 2
Outcomes and estimation	17	For each objective, results including expressions of uncertainty (such as 95% confidence interval) for any estimates. If relevant, these results should be by randomised group	163-214
Ancillary analyses	18	Results of any other analyses performed that could be used to inform the future definitive trial	228-238
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	None
	19a	If relevant, other important unintended consequences	None
Discussion			
Limitations	20	Pilot trial limitations, addressing sources of potential bias and remaining uncertainty about feasibility	324-337
Generalisability	21	Generalisability (applicability) of pilot trial methods and findings to future definitive trial and other studies	269-273, 308-312
Interpretation	22	Interpretation consistent with pilot trial objectives and findings, balancing potential benefits and harms, and considering other relevant evidence	260-269, 274-286
	22a	Implications for progression from pilot to future definitive trial, including any proposed amendments	339-356
Other information			
Registration	23	Registration number for pilot trial and name of trial registry	65
Protocol	24	Where the pilot trial protocol can be accessed, if available	360-367

Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	143-150
	26	Ethical approval or approval by research review committee, confirmed with reference number	71 (Yale IRB #2000030105)

Citation: Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) license (http://creativecommons.org/licenses/by/3.0/), which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.

*We strongly recommend reading this statement in conjunction with the CONSORT 2010, extension to randomised pilot and feasibility trials, Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up-to-date references relevant to this checklist, see www.consort-statement.org.